GE HealthCare's new MIM Symphony HDR Prostate solution is now improving the precision of high dose-rate (HDR) prostate brachytherapy treatments by incorporating guidance from preoperative magnetic resonance imaging (MRI). By enabling clinicians to view MRI contours on live ultrasound during HDR procedures, this innovative instrument aims to enhance patient outcomes and boost clinician confidence by enabling direct tumor visualization.
In HDR brachytherapy, radioactive sources are inserted into the prostate organ through needles to treat prostate cancer. The planning of these procedures has traditionally been conducted using computed tomography (CT) or ultrasound imaging. While the integration of magnetic resonance imaging (MRI) into the planning of brachytherapy treatment has been shown to mitigate toxicity to critical structures, the alignment of MRI contours with live ultrasound images has proven to be a difficult task.
MIM Symphony HDR Prostate, which was created by GE HealthCare's MIM Software, resolves this issue by harmonizing preoperatively acquired MRI contours with live ultrasound. This approach provides a clear view of the prostate, lesions, and critical structures during HDR procedures. The new solution is part of GE HealthCare's MIM Software portfolio, which includes MIM Maestro, Contour ProtégéAI+, and MIM Symphony LDR. GE HealthCare offers an array of integrated services, solutions, and data analytics aimed to enhance the efficiency of hospitals, the effectiveness of clinicians, the precision of therapies, and the well-being and happiness of patients.
